2027 Agenda: Day 1 - Monday 11 January - PT (Pacific Time, GMT-08:00)
The biopharma industry’s mission is to advance global healthcare. But cutting-edge scientific potential is increasingly hampered by socioeconomic and regulatory pressures that conflict with this mission. Sustaining high-risk innovation requires navigating complex public perceptions and policy environments.
The Syneos Health Dealmakers’ Intentions Study is a forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries. Now in its 18th year, this survey provides a unique perspective on these trends by surveying business development professionals from pharmaceutical and biotechnology companies of all sizes to create forward-looking insights based on dealmakers' general expectations for activity in the coming year. This session will discuss the results of this year’s Dealmakers’ Intentions Study, providing a prospective view of the partnering and licensing landscape for the year ahead.
Biopharma’s higher calling is to turn breakthrough science into medicines that transform lives. And today, they not only look to biotech as a source of early-stage ideas but also as one of the main ways to renew their pipelines and fulfil their higher calling.
Explore how AI, data, and emerging technologies are transforming MedTech, devices, and TechBio—unlocking smarter discovery, sharper insights, and new pathways to value creation.